Amphastar P (AMPH)
Profitability ratios
Return on sales
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross profit margin | 54.49% | 54.24% | 51.07% | 51.46% | 49.87% | 48.25% | 47.51% | 46.28% | 45.63% | 43.69% | 43.14% | 41.14% | 40.97% | 41.47% | 41.51% | 42.12% | 40.92% | 40.54% | 39.26% | 38.26% |
| Operating profit margin | 30.57% | 30.07% | 24.29% | 23.01% | 21.54% | 19.37% | 20.02% | 17.84% | 15.96% | 11.75% | 7.10% | 3.74% | 3.13% | 2.32% | 2.01% | 3.24% | -0.01% | 0.53% | 0.59% | -0.64% |
| Pretax margin | 26.28% | 28.23% | 23.84% | 23.01% | 23.02% | 20.75% | 23.99% | 23.04% | 18.90% | 11.77% | 4.83% | 1.33% | 1.41% | 3.43% | 2.18% | 21.24% | 19.44% | 19.47% | 20.19% | -0.23% |
| Net profit margin | 21.34% | 22.50% | 18.85% | 17.96% | 18.31% | 15.93% | 19.06% | 17.87% | 14.19% | 8.74% | 2.72% | 0.68% | 0.40% | 1.97% | 1.21% | 15.90% | 15.18% | 15.77% | 16.33% | 0.72% |
Amphastar Pharmaceuticals Inc has shown consistent improvement in its profitability ratios over the past eight quarters. The gross profit margin has been steadily increasing from 46.28% in Q1 2022 to 54.49% in Q4 2023, indicating the company's ability to efficiently manage its production costs.
The operating profit margin has also shown a positive trend, increasing from 17.84% in Q1 2022 to 30.57% in Q4 2023. This suggests that the company has been able to effectively control its operating expenses while generating higher revenues.
Similarly, the pretax margin has demonstrated a favorable trajectory, improving from 20.75% in Q3 2022 to 28.23% in Q3 2023. This indicates that the company has been successful in managing its pre-tax earnings relative to its total revenue.
Finally, the net profit margin has shown consistent growth, rising from 15.93% in Q3 2022 to 22.50% in Q3 2023. This indicates that the company has been able to increase its profitability after accounting for all expenses including taxes.
Overall, the improving trend in all profitability ratios reflects the strong operational performance and financial health of Amphastar Pharmaceuticals Inc over the analyzed period.
Return on investment
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating return on assets (Operating ROA) | 13.02% | 11.71% | 9.53% | 15.42% | 14.49% | 12.92% | 13.19% | 11.34% | 10.41% | 7.44% | 4.09% | 2.13% | 1.74% | 1.28% | 1.12% | 1.85% | -0.01% | 0.30% | 0.32% | -0.37% |
| Return on assets (ROA) | 9.09% | 8.76% | 7.40% | 12.04% | 12.32% | 10.63% | 12.56% | 11.35% | 9.25% | 5.54% | 1.57% | 0.39% | 0.22% | 1.08% | 0.67% | 9.08% | 8.34% | 8.85% | 8.80% | 0.42% |
| Return on total capital | 15.82% | 15.06% | 22.74% | 22.09% | 19.28% | 20.21% | 23.20% | 22.11% | 15.97% | 11.48% | 4.50% | 1.31% | 1.19% | 2.64% | 1.87% | 18.45% | 14.68% | 16.45% | 16.92% | -0.14% |
| Return on equity (ROE) | 21.51% | 22.73% | 17.30% | 16.98% | 17.29% | 15.29% | 18.21% | 16.96% | 13.94% | 8.39% | 2.48% | 0.62% | 0.35% | 1.47% | 1.02% | 13.78% | 12.83% | 13.31% | 13.64% | 0.68% |
Amphastar Pharmaceuticals Inc's profitability ratios depict a fluctuating trend over the past few quarters. The operating return on assets (Operating ROA) has displayed a slight increase from Q1 2023 to Q4 2023, indicating the company's ability to generate operating income relative to its total assets has improved. However, the Return on Assets (ROA) shows a more erratic pattern, with a peak in Q1 2023 but a decline in subsequent quarters.
The Return on Total Capital exhibits a similar trend to the Operating ROA, illustrating an uptick in profitability from Q1 2023 to Q4 2023. This ratio measures the overall return generated by both debt and equity capital invested in the business. On the other hand, the Return on Equity (ROE) has been fluctuating with varying levels of return to equity investors.
In summary, while the Operating ROA and Return on Total Capital display a relatively positive trend in recent quarters, the overall profitability of Amphastar Pharmaceuticals Inc, as indicated by ROA and ROE, has been more inconsistent. Further analysis of the company's financial performance and underlying factors driving these ratios would be necessary to fully understand their implications on the company's profitability and future prospects.